Anaheim Clinical Trials (ACT), an adult and pediatric Phase I through Phase IV clinical research center recently purchased a FibroScan®.
Anaheim, California (August 28, 2018) -- Anaheim Clinical Trials (ACT), an adult and pediatric Phase I through Phase IV clinical research center recently purchased a FibroScan®. This non-invasive imaging device uses ultrasound-like technology to measure the degree of liver scarring or fibrosis caused by various liver diseases, including Hepatitis, nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). This device will allow more accurate screening for subject selection in liver studies and may eliminate the need for unnecessary liver needle biopsies for diagnosis of NASH/NAFLD in some subjects.
“As a Gastroenterologist and Principal Investigator, I expect the FibroScan® to provide a preliminary, non-invasive diagnosis for potential study subjects who volunteer for NASH/NAFLD trials. Subjects with a negative result will screen fail and avoid a diagnostic liver needle biopsy as the next step. It’s important that our potential subjects not undergo unnecessary and invasive tests during the screening process,” said Dr. Peter Winkle, M.D., F.A.C.G, F.A.C.P., C.P.I., Medical Director. “The preliminary diagnosis provided using this device should shorten enrollment times by preventing unnecessary liver biopsies in potential subjects that unlikely have the disease.”
“Furthermore, shortening total enrollment or study timelines will also decrease the overall study costs,” added Patrick McLaughlin, CEO. “Our customers are interested in conducting trials efficiently and cost-effectively, as well as limiting undo risk to potential subjects.”
About Anaheim Clinical Trials
Anaheim Clinical Trials (ACT) is an adult and pediatric Phase I clinical research center with full-service CRO capabilities, located in southern California (Anaheim). In addition to healthy volunteers, ACT has been particularly successful in enrolling special patient populations in complex trials and Japanese subjects for ethno-bridging trials. Our certified Principal Investigators have the expertise and interest in a wide variety of therapeutic areas, including GI, CNS, pain, metabolic/inflammation, infectious disease, and respiratory. ACT has been recognized by our customers for excellent quality research, timeliness, high patient enrollment, and ease of doing business. For more information about ACT, please visit our website at http://act-trials.com.
For more information, please contact Linda Gundaker, Executive Vice President, via email at lgundaker@act-trials.com or mobile at 610-937-2006.
CONFIDENTIALITY NOTICE: This E-Mail is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you have received this communication in error, please do not distribute it. Please notify the sender by E-Mail at the address shown and delete the original message. Thank you.
